In vivo microdialysis for PK and PD studies of anticancer drugs - PubMed (original) (raw)

Review

In vivo microdialysis for PK and PD studies of anticancer drugs

Qingyu Zhou et al. AAPS J. 2005.

Abstract

In vivo microdialysis technique has become one of the major tools to sample endogenous and exogenous substances in extracellular spaces. As a well-validated sampling technique, microdialysis has been frequently employed for quantifying drug disposition at the desired target in both preclinical and clinical settings. This review addresses general methodological considerations critical to performing microdialysis in tumors, highlights selected preclinical and clinical studies that characterized drug disposition in tumors by the use of microdialysis, and illustrates the potential application of microdialysis in the assessment of tumor response to cancer treatment.

PubMed Disclaimer

Similar articles

• Microdialysis for pharmacokinetic-pharmacodynamic studies.
  Yu W, Cheng Q, Feng J, Li F. Yu W, et al. Pharmazie. 2007 Dec;62(12):883-91. Pharmazie. 2007. PMID: 18214337 Review.
• Microdialysis: a technique for pharmacokinetic-pharmacodynamic studies of oncological drugs.
  Wei YH, Xu LZ, Shen Q, Li FZ. Wei YH, et al. Curr Pharm Biotechnol. 2009 Sep;10(6):631-40. doi: 10.2174/138920109789069288. Epub 2009 Sep 1. Curr Pharm Biotechnol. 2009. PMID: 19619119 Review.
• Microdialysis: an in vivo approach for measuring drug delivery in oncology.
  Brunner M, Müller M. Brunner M, et al. Eur J Clin Pharmacol. 2002 Jul;58(4):227-34. doi: 10.1007/s00228-002-0475-0. Epub 2002 May 23. Eur J Clin Pharmacol. 2002. PMID: 12136367 Review.
• Application of microdialysis to characterize drug disposition in tumors.
  Chu J, Gallo JM. Chu J, et al. Adv Drug Deliv Rev. 2000 Dec 15;45(2-3):243-53. doi: 10.1016/s0169-409x(00)00115-0. Adv Drug Deliv Rev. 2000. PMID: 11108977 Review.
• Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.
  Loos WJ, Zamboni WC, Engels FK, de Bruijn P, Lam MH, de Wit R, Verweij J, Wiemer EA. Loos WJ, et al. J Pharm Biomed Anal. 2007 Oct 18;45(2):288-94. doi: 10.1016/j.jpba.2007.07.023. Epub 2007 Jul 26. J Pharm Biomed Anal. 2007. PMID: 17804188

Cited by

• New strategies to deliver anticancer drugs to brain tumors.
  Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. Laquintana V, et al. Expert Opin Drug Deliv. 2009 Oct;6(10):1017-32. doi: 10.1517/17425240903167942. Expert Opin Drug Deliv. 2009. PMID: 19732031 Free PMC article. Review.
• Revolutionizing Therapeutic Drug Monitoring with the Use of Interstitial Fluid and Microneedles Technology.
  Kiang TKL, Ranamukhaarachchi SA, Ensom MHH. Kiang TKL, et al. Pharmaceutics. 2017 Oct 11;9(4):43. doi: 10.3390/pharmaceutics9040043. Pharmaceutics. 2017. PMID: 29019915 Free PMC article. Review.
• Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
  Grossman R, Tyler B, Rudek MA, Kim E, Zadnik P, Khan U, Blakeley JO, Pathak AP, Brem H. Grossman R, et al. Cancer Chemother Pharmacol. 2013 Jul;72(1):93-100. doi: 10.1007/s00280-013-2172-3. Epub 2013 May 7. Cancer Chemother Pharmacol. 2013. PMID: 23649683 Free PMC article.
• Does PAD and microcirculation status impact the tissue availability of intravenously administered antibiotics in patients with infected diabetic foot? Results of the DFIATIM substudy.
  Fejfarová V, Jarošíková R, Antalová S, Husáková J, Wosková V, Beca P, Mrázek J, Tůma P, Polák J, Dubský M, Sojáková D, Lánská V, Petrlík M. Fejfarová V, et al. Front Endocrinol (Lausanne). 2024 May 7;15:1326179. doi: 10.3389/fendo.2024.1326179. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38774229 Free PMC article.
• Interstitial fluid: the overlooked component of the tumor microenvironment?
  Wiig H, Tenstad O, Iversen PO, Kalluri R, Bjerkvig R. Wiig H, et al. Fibrogenesis Tissue Repair. 2010 Jul 23;3:12. doi: 10.1186/1755-1536-3-12. Fibrogenesis Tissue Repair. 2010. PMID: 20653943 Free PMC article.

References

1. 1. Galmarini CM, Galmarini FC. Multidrug resistance in cancer therapy: role of the microenvironment. Curr Opin Investig Drugs. 2003;4:1416–1421. - PubMed
2. 1. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In:Important Adv Oncol. 1988:121–141. - PubMed
3. 1. Masson E, Zamboni WC. PK optimisation of cancer chemotherapy: effect on outcomes. Clin Pharmacokinet. 1997;32:324–343. doi: 10.2165/00003088-199732040-00005. - DOI - PubMed
4. 1. Yuan F. Transvascular drug delivery in solid tumors. Semin Radiat Oncol. 1998;8:164–175. doi: 10.1016/S1053-4296(98)80042-8. - DOI - PubMed
5. 1. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46:149–168. doi: 10.1016/S0169-409X(00)00131-9. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Springer

• Research Materials

  • NCI CPTC Antibody Characterization Program